TLDR
Moderna stock jumps 7.38% to $259.25 following strong third-quarter results.
Quarterly revenue climbs 29% to $1.3 billion as overseas vaccine sales rise.
Moderna swings to a $162 million quarterly profit, with EPS reaching $0.38.
Moderna lifts its 2026 revenue growth forecast to 15%-25% after strong sales.
Phase 3 melanoma data show a 42% drop in recurrence or death risk with therapy.
Moderna (MRNA) shares jumped 7.38% to $259.25 after the company reported higher sales and positive cancer results. The stock gained $17.79 and recovered from an intraday low near $241.46. Higher annual revenue guidance added further support for the stock’s rally.
Moderna, Inc., MRNA
Moderna Reports Higher Revenue and Returns to Profit
Moderna generated $1.3 billion in third-quarter revenue, up 29% from $1.0 billion a year earlier. International vaccine demand and government agreements supported growth. U.S. sales totaled $780 million, while international markets contributed another $533 million.
The company posted $162 million in net income after recording a $200 million loss last year. Diluted earnings reached $0.38 per share, compared with a $0.51 loss per share previously. Meanwhile, research spending declined 27% to $583 million as Moderna reduced late-stage clinical development costs.
Cost of sales increased 54% to $318 million alongside higher vaccine volumes and manufacturing expenses. Selling, general, and administrative costs rose 5% to $282 million this quarter. Sales growth and lower research costs offset higher production expenses across operations.
Moderna Raises Revenue and Cash Forecasts for 2026
Moderna now expects annual revenue growth between 15% and 25%, above its previous forecast of 10% maximum. U.S. and international markets should contribute roughly equal revenue shares. The forecast follows expanded deliveries and commercial partnerships in several international markets.
Management reduced its full-year research spending forecast from $2.9 billion to approximately $2.7 billion. The company maintained its $1.0 billion administrative expense projection and expects capital spending near $200 million. It also expects approximately $1.7 billion in cost of sales, including litigation settlement costs.
Moderna raised its year-end cash forecast to $8.1 billion through $8.3 billion. Previously, the company projected a range of $4.7 billion to $5.2 billion. September financing provided approximately $2.6 billion in net proceeds and strengthened its cash position.
Cancer Trial Results Expand Moderna’s Pipeline Progress
Moderna and Merck reported positive Phase 3 melanoma results for intismeran autogene combined with Keytruda. The combination reduced recurrence or death risk by 42% compared with Keytruda alone. It also lowered the risk of distant metastasis or death by 38% in the study.
The companies plan regulatory submissions and preparations for a possible launch after securing approval. Separately, U.S. regulators approved Moderna’s mFLUSIVA influenza vaccine for adults aged 50 through 64. Regulators also granted accelerated approval for adults aged 65 and older.
Moderna expects pivotal results from its propionic acidemia program before the end of 2026. Meanwhile, its norovirus vaccine missed the interim threshold for early success in Phase 3 testing. These updates show clinical progress alongside development setbacks across its portfolio.
The post Moderna (MRNA) Stock: Rally 7.38% as $1.3B Revenue and Positive Cancer Trial Results Boost Optimism appeared first on Blockonomi .
